Biotechnology,
Health,
Pharmaceutical,
Clinical Trials,
Oncology,
Chronic myelomonocytic leukemia,
Survival,
Granulocyte-macrophage colony-stimulating factor,
Mortality,
Hercules,
Rating,
ATM,
Research,
Patient,
Term loan,
COVID-19,
Haematopoietic system,
Research and development,
GM-CSF,
National,
Lymphatic system,
Nasdaq,
Pharmaceutical industry,
Tutoring,
Cryptocurrency,
CMML Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the second quarter and six months ended June 30, 2022.
Key Points:
- Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the second quarter and six months ended June 30, 2022.
- Second Quarter and Six Months Ended June 30, 2022 Financial Results
Net loss for the quarter ended June 30, 2022 was $30.1 million, or $0.43 per share, as compared to $70.8 million, or $1.20 per share, for the quarter ended June 30, 2021.
- The decrease in R&D expense is primarily due to decreased lenzilumab manufacturing costs for the quarter ended June 30, 2022 of $34.6 million, and for the six months ended June 30, 2022 of $70.3 million.
- Subsequent to end of the quarter and through August 10, 2022, the company raised an additional $15.9 million under the ATM.
Stem Cells,
Biotechnology,
Pharmaceutical,
Oncology,
General Health,
Health,
Infectious Diseases,
Clinical Trials,
SHIELD,
United Kingdom,
COVID-19,
CMA,
U.S. Securities and Exchange Commission,
Forward-looking statement,
Twitter,
Nasdaq,
Neurotoxicity,
EUA,
Company,
NIH,
Safety,
Chronic myelomonocytic leukemia,
Asthma,
Centers for Disease Control and Prevention,
Judgement,
CDC,
Chemokine,
Patient,
Cytokine release syndrome,
Security (finance),
Projection,
RAS,
GM-CSF,
FDA,
Inflammation,
Risk,
Therapy,
Knowledge,
Center,
Degenerative disease,
Gilead Sciences,
LinkedIn,
GM,
Goal,
Non-Hodgkin lymphoma,
Rheumatoid arthritis,
Graft-versus-host disease,
Granulocyte-macrophage colony-stimulating factor,
Vaccine,
Pharmaceutical industry,
Lenzilumab,
Facebook Based on these results, Humanigen plans to test lenzilumab in a randomized, multicenter, potentially registrational, Phase 3 SHIELD study to evaluate its efficacy and safety when combined with Yescarta and Tecartus CAR-T therapies in non-Hodgkin lymphoma.
Key Points:
- Based on these results, Humanigen plans to test lenzilumab in a randomized, multicenter, potentially registrational, Phase 3 SHIELD study to evaluate its efficacy and safety when combined with Yescarta and Tecartus CAR-T therapies in non-Hodgkin lymphoma.
- Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm.
- Results from preclinical models indicate GM-CSF is an upstream regulator of many inflammatory cytokines and chemokines involved in the cytokine storm.
- Retrieved May 4, 2022, from https://www.roche.com/investors/events/annual-results-2021
LENZ and Humaneered are trademarks of Humanigen, Inc.
Yescarta and Tecartus are trademarks of Gilead Sciences, Inc., or its related companies.
Science,
Stem Cells,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
Health,
Clinical Trials,
SHIELD,
Chronic myelomonocytic leukemia,
Cytokine release syndrome,
Infection,
CMML,
The Lancet,
DLBCL,
National Institute of Allergy and Infectious Diseases,
Research,
COVID-19,
Oxygen toxicity,
National,
Clinical trial,
Rating,
Sale,
Safety,
Degenerative disease,
Neurotoxicity,
Steroid,
Emergency Use Authorization,
ORR,
EUA,
FDA,
R,
Nasdaq,
Patient,
Union,
CRS,
Survival,
C-reactive protein,
Standard of care,
B-cell lymphoma,
National Institute,
Research and development,
Pharmaceutical industry,
Lenzilumab,
Lancet Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today reported financial results for the year ended December 31, 2021, and announced corporate objectives for 2022.
Key Points:
- Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today reported financial results for the year ended December 31, 2021, and announced corporate objectives for 2022.
- Net cash used in operating activities, net of balance sheet changes, was $184.0 million for the year ended December 31, 2021.
- Subsequent to December 31, 2021, the company raised net proceeds of approximately $3.7 million under its At-the-Market offering program.
- A summary of key financial highlights as of and for the years ended December 31, 2021 and 2020 is as follows ($ in thousands):
Three Months Ended December 31,
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Biotechnology,
Patient,
Judgement,
Security (finance),
GM-CSF,
Risk,
The Lancet,
Conditional,
Forward-looking statement,
Company,
Rheumatoid arthritis,
Medication,
Graft-versus-host disease,
Chemokine,
Inflammation,
U.S. Securities and Exchange Commission,
COVID-19,
Goal,
ICU,
Nasdaq,
Twitter,
Survival,
United Kingdom,
Knowledge,
GM,
Webcast,
LinkedIn,
Granulocyte-macrophage colony-stimulating factor,
Pharmaceutical industry,
Hospital Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm, announced that it will host a conference call and webcast to discuss The Lancet Respiratory Medicine publications and provide a corporate update at 8am EST on December 2, 2021.
Key Points:
- Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm, announced that it will host a conference call and webcast to discuss The Lancet Respiratory Medicine publications and provide a corporate update at 8am EST on December 2, 2021.
- Lenzilumab is a first-in class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF).
- Results from preclinical models indicate GM-CSF is an upstream regulator of many inflammatory cytokines and chemokines involved in the cytokine storm.
- Humanigens Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent cytokine storm in hospitalized patients with COVID-19.
Health,
Infectious Diseases,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Patient,
2021 Essex County Council election,
Government,
British Thoracic Society,
CEO,
C-reactive protein,
Death,
MD,
CRP,
Pulmonary alveolar proteinosis,
COVID-19,
Nasdaq,
Chief executive officer,
Incidence,
Nursing,
United Kingdom,
Randomness,
Pharmaceutical industry,
ISARIC Coronavirus Clinical Characterisation Consortium (4C) Mortality Score,
Humanigen, Inc.,
ISARIC CORONAVIRUS CLINICAL CHARACTERISATION CONSORTIUM (4C) MORTALITY SCORE,
HUMANIGEN, INC. Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced three abstracts pertaining to the potential use of lenzilumab in hospitalized COVID-19 patients will be presented at the British Thoracic Society Winter 2021 Meeting taking place Nov. 24-26, 2021.
Key Points:
- Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced three abstracts pertaining to the potential use of lenzilumab in hospitalized COVID-19 patients will be presented at the British Thoracic Society Winter 2021 Meeting taking place Nov. 24-26, 2021.
- The society counts more than 4,000 members comprised of doctors, nurses, respiratory physiotherapists, scientists, and other professionals with a respiratory interest.
- The study also demonstrated significant improvement in SWOV for the predefined subgroup of subjects who received both corticosteroids and remdesivir (HR: 1.92; nominal p=0.0067).
- Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm.
Science,
Stem Cells,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
Health,
Clinical Trials,
Medication,
GM,
COO,
Chemokine,
Graft-versus-host disease,
Security (finance),
Knowledge,
Granulocyte-macrophage colony-stimulating factor,
Inflammation,
Rheumatoid arthritis,
Goal,
COVID-19,
Forward-looking statement,
Risk,
Judgement,
Twitter,
Conference,
U.S. Securities and Exchange Commission,
Company,
LinkedIn,
GM-CSF,
Nasdaq,
Patient,
United Kingdom,
CFO,
Conditional,
Vaccine,
Pharmaceutical industry Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm, announced that its presentation time at the Jefferies London Healthcare Conference has been changed.
Key Points:
- Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm, announced that its presentation time at the Jefferies London Healthcare Conference has been changed.
- Timothy Morris, COO and CFO, will now make a corporate presentation at 9:20am EST on November 17, 2021.
- Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm.
- Humanigen has submitted lenzilumab to Medicines and Health Regulatory Agency in the United Kingdom for a rolling review towards potential Conditional Marketing Authorization.
Science,
Stem Cells,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
Health,
Clinical Trials,
Population,
Safety,
University,
CD19,
GM,
Authorization,
Degenerative disease,
University of Birmingham,
Conditional,
MAA,
European Commission,
Graft-versus-host disease,
Infection,
MHRA,
Disease,
CEO,
National,
EMA,
COVID,
COVID-19,
CMML,
Non-Hodgkin lymphoma,
Rapporteur,
Hospital,
Risk management,
Holocene,
CMA,
CRP,
Access,
Time,
Chronic myelomonocytic leukemia,
Royal commission,
Vaccination,
Patent,
NHL,
Nasdaq,
Patient,
NIH,
FDA,
Pharmaceutical industry,
Animal Humanigen submitted the last of the planned modules on September 30, 2021.
Key Points:
- Humanigen submitted the last of the planned modules on September 30, 2021.
- Third Quarter and Recent Highlights:
European Commission selected Humanigens lenzilumab as one of the 10 most promising treatments for COVID-19.
- Subsequent to September 30, 2021, the company received net proceeds of approximately $24.5 million under its At-the-Market offering program.
- A summary of key financial highlights as of and for the three and nine months ended September 30, 2021 and 2020 is as follows ($ in thousands):
Three Months Ended September 30,
Nine Months Ended September 30,